Effects of renal impairment on the pharmacokinetics of orally administered deferiprone.

ABSTRACT:

Aims

In light of the growing recognition of renal disease in thalassemia, it is important to understand the impact of renal impairment on the pharmacokinetics of iron chelators. This study evaluated the pharmacokinetics and safety of the iron chelator deferiprone (DFP) in subjects with renal impairment in comparison with healthy volunteers (HVs).

Methods

Thirty-two subjects were categorized into four groups based on degree of renal impairment: none, mild, moderate or severe, as determined by estimated glomerular filtration rate (eGFR). All subjects received a single oral dose of 33 mg kg(-1) DFP, provided serum and urine samples for pharmacokinetic assessment over 24 h and were monitored for safety.

Results

Renal clearance of DFP decreased as renal impairment increase

SUBMITTER: Fradette C 

PROVIDER: S-EPMC5137824 | biostudies-literature | 2016 Oct

REPOSITORIES: biostudies-literature